This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
It is no longer the current profile. Read the canonical profile and its correction notice.
Correction · September 15, 2026
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct. 2
What this version reported
FDA's July 2026 briefing evaluates MOTS-c-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.↗
Sources for this version
- 1Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2FDA briefing document for MOTS-c ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026